Company Overview - Northisle Copper & Gold Inc. is based in Vancouver, BC, and focuses on copper, gold, molybdenum, and rhenium [4] - The company aims to become Canada's leading sustainable mineral resource company [4] - Northisle owns the North Island Project, a significant copper and gold porphyry project located near Port Hardy, British Columbia, covering over 34,000 hectares [4] Recent Developments - The company will present live at the Metals & Mining Virtual Investor Conference on July 23, 2025, from 1:00 pm to 1:30 pm ET [1] - Investors can participate in 1x1 meetings from July 23 to July 29, 2025 [1] - An archived webcast will be available for those unable to attend the live event [1] Project Highlights - Since 2021, Northisle has discovered two significant deposits and expanded resources at the North Island Project [4] - The company is focused on accelerating the advancement of this project while exploring within its highly prospective land package [4] Investor Engagement - Virtual Investor Conferences (VIC) provides an interactive platform for publicly traded companies to present directly to investors [6] - VIC enhances investor access and engagement through targeted one-on-one meetings and dynamic video content [7]

Vancouver, British Columbia – TheNewswire - July 16, 2025 – Fitzroy Minerals Inc. (“Fitzroy” or the “Company”) (TSXV: FTZ) is pleased to provide strategic and exploration updates after its recent financing (see Fitzroy news release July 9, 2025). Following excellent exploration results in H1 2025, at both the Buen Retiro Copper (“Buen Retiro”) and Caballos (“Caballos”) Copper-Molybdenum-Gold-Rhenium projects, the Company will focus primarily on advancing these two projects. Further, the Company will review ...

Core Insights - Plus Therapeutics, Inc. is advancing its ReSPECT-LM dose optimization trial for REYOBIQ, targeting leptomeningeal metastases (LM) with initial patient treatments underway [1][2] - The trial aims to identify optimal dosing regimens to maximize efficacy and safety, building on positive results from a previous Phase 1 study [3][4] - The company anticipates rapid enrollment due to the lack of FDA-approved therapies for LM and expects to complete Cohort 1 by the end of the year [2][4] Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers [11] - The company’s lead product, REYOBIQ, is designed to deliver high-dose radiation directly to CNS tumors, potentially improving patient outcomes compared to existing therapies [8][11] - The ReSPECT-LM trial is supported by a $17.6 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT), a significant funding source for cancer research [6][9] Clinical Trial Details - The ReSPECT-LM trial's primary objectives include determining the safety and tolerability of multiple REYOBIQ doses and identifying the maximum tolerated dose and minimum effective dose [3] - The previous Phase 1 trial demonstrated that a single dose of REYOBIQ could deliver an average absorbed dose of over 250 Gy, with significant tumor reduction observed in patients [4] - Data from the completed Phase 1 study will be presented at the upcoming SNO/ASCO CNS Metastases Conference in August 2025 [5] Industry Context - Leptomeningeal metastases occur in approximately 5% of patients with metastatic cancer, with limited treatment options available, highlighting the need for innovative therapies [7] - REYOBIQ is being evaluated for multiple indications, including recurrent glioblastoma and pediatric brain cancer, indicating a broad potential application in CNS oncology [8][9]

Core Viewpoint - Plus Therapeutics has initiated the ReSPECT-LM dose optimization trial for REYOBIQ™ to determine the optimal dosing schedule for treating leptomeningeal metastases, building on previous trial results and supported by a $17.6 million grant from CPRIT [1][7]. Trial Design and Objectives - The trial aims to optimize treatment dosing for maximum efficacy and safety, focusing on the safety and tolerability of multiple REYOBIQ doses administered via intraventricular catheter [2]. - Primary objectives include identifying the maximum tolerated dose and minimum effective dose for patients with LM from any primary solid tumor cancer [2]. Enrollment and Study Details - The trial will enroll up to 24 patients, evaluating REYOBIQ at a recommended Phase 2 dose of 44.1 mCi across three dosing intervals [4]. - Key cohorts include dosing intervals of 56 days, 28 days, and 14 days, with up to six patients per cohort [4]. Efficacy and Safety Data - Previous trials showed a clinical benefit rate of 76%, with 29% of patients achieving partial responses and 47% maintaining stable disease [5]. - No dose-limiting toxicities were observed in the first four cohorts, although one Grade 4 DLT occurred in each of Cohorts 5 and 6 [5]. Future Plans - The company plans to present data from the completed single-dose escalation trial at the SNO/ASCO CNS Metastases Conference in August 2025 and will request an End of Phase 1 Type B meeting with the FDA [6]. About Leptomeningeal Metastases - Leptomeningeal metastases occur in approximately 5% of patients with metastatic cancer, with median survival typically ranging from 2 to 6 months, highlighting the urgent need for effective treatment options [8]. About REYOBIQ™ - REYOBIQ™ is a novel injectable radiotherapy designed for targeted high-dose radiation in CNS tumors, with potential advantages over currently approved therapies [9]. Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for challenging CNS cancers, with a pipeline that includes treatments for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancer [10].

Core Insights - Plus Therapeutics has received FDA clearance for its Investigational New Drug application for REYOBIQ, aimed at treating pediatric patients with high-grade glioma and ependymoma [2][5] - The Phase 1/2a trial, named ReSPECT-PBC, is supported by a $3 million grant from the U.S. Department of Defense and will focus on determining the maximum tolerated dose and safety of REYOBIQ in children aged 6 to 21 [1][4][7] Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company based in Houston, Texas, specializing in targeted radiotherapeutics for central nervous system cancers [9] - The company is advancing a pipeline that includes treatments for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer [9] Trial Design and Objectives - The ReSPECT-PBC trial is a two-part, single-arm study designed to assess the safety and tolerability of REYOBIQ, with a focus on pediatric patients with rare and aggressive brain tumors [4][7] - The trial will enroll approximately 56 patients, with 24 in Phase 1a for dose escalation and 32 in Phase 2a to assess efficacy [7] Treatment Potential - REYOBIQ is designed to deliver high doses of beta radiation directly to brain tumors while minimizing damage to surrounding healthy tissue, potentially improving outcomes for patients with limited treatment options [5][8] - The targeted delivery method via convection enhanced delivery (CED) aims to bypass the blood-brain barrier, which is a significant challenge in treating CNS tumors [4][5]

VANCOUVER, British Columbia, June 10, 2025 (GLOBE NEWSWIRE) -- Sable Resources Ltd. ("Sable" or the "Company") (TSXV:SAE | OTCQB:SBLRF) is pleased to announce results from three of four holes drilled from February to April 2025 at the Pyros porphyry system, within the El Fierro Project in San Juan province, Argentina. The drilling campaign was funded by Moxico Resources plc ("Moxico") in accordance with the Letter Agreement signed between the Company and Moxico on February 27, 2025. Drilling Highlights FZ-D ...

Core Viewpoint - Plus Therapeutics, Inc. (PSTV) experienced a significant share price increase of 170.1% following the FDA's conditional acceptance of the proprietary name "Reyobiq" for its lead therapeutic candidate, rhenium Re186 obisbemeda [1] Company Developments - The company will now use the proprietary name Reyobiq for all communications related to the previously adopted generic name rhenium Re186 obisbemeda [2] - Reyobiq is being developed as a novel injectable radiotherapy aimed at delivering targeted high-dose radiation for central nervous system tumors, potentially improving patient outcomes [2] - Plus Therapeutics is focusing on Reyobiq for treating leptomeningeal metastases (LM) and recurrent glioblastoma (GBM) [4] - The FDA granted Orphan Drug Designation to Reyobiq for treating LM in lung cancer patients, a rare complication where cancer spreads to the cerebrospinal fluid [4] - Enrollment for the ReSPECT-LM phase I study has been completed, which will assess the safety and efficacy of Reyobiq in patients with LM [5] - The company is preparing for a phase II single-dose expansion study and a phase I multiple-dose study for Reyobiq in LM patients [5] - Reyobiq is also being evaluated in the phase I/II ReSPECT-GBM study for recurrent glioblastoma treatment [6] Market Performance - Over the past year, shares of Plus Therapeutics have declined by 26.2%, while the industry average has decreased by 6.7% [3]

深夜暴涨。 拼多多董事长兼联席CEO陈磊在财报中表示："2024年，公司致力于推动平台生态系统和更广泛供应链的可持续发展。通过对平台运营和行业支持政策的针对 性创新，公司将继续推动高质量发展战略，从而使更广泛的电子商务生态系统受益。"陈磊称，过去几个季度拼多多在生态建设上投入，帮助平台更好应对消 费变化、产业转型以及行业竞争。 当地时间3月20日（周四），美股三大指数集体小幅收跌，截至收盘，道琼斯指数微跌0.03%，标普500指数下跌0.22%，纳斯达克指数下跌0.33%。热门科技 股多数下跌，苹果、亚马逊、谷歌A、微软跌幅均在1%以内，而特斯拉、英伟达和Meta微涨。 中概股集体大跌，纳斯达克中国金龙指数跌下3.84%，创下了2月25日以来最大的单日跌幅。 此外，制药公司PlusTherapeutics大涨170.06%，换手率达5897.62%，盘中涨幅一度超过300%，多次熔断。PlusTherapeutics此前曾宣布，其针对肺癌患者软脑 膜转移的治疗药物Rhenium(186Re) Obisbemeda获得美国食品药品监督管理局（FDA）"孤儿药"资格认定。 | us Plus Therapeuti ...